215 related articles for article (PubMed ID: 36330916)
1. Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors.
Yan X; Liu P; Li D; Hu R; Tao M; Zhu S; Wu W; Yang M; Qu X
Int Immunopharmacol; 2022 Dec; 113(Pt A):109383. PubMed ID: 36330916
[TBL] [Abstract][Full Text] [Related]
2. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment.
Wang Y; Yang M; Tao M; Liu P; Kong C; Li H; Chen Y; Yin X; Yan X
Int Immunopharmacol; 2021 Oct; 99():108031. PubMed ID: 34358857
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
[TBL] [Abstract][Full Text] [Related]
7. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
8. Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors.
Yan X; Wang J; Mao J; Wang Y; Wang X; Yang M; Qiao H
Front Nutr; 2023; 10():1213255. PubMed ID: 37575320
[TBL] [Abstract][Full Text] [Related]
9. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
Front Immunol; 2022; 13():968729. PubMed ID: 35967438
[TBL] [Abstract][Full Text] [Related]
10. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
[TBL] [Abstract][Full Text] [Related]
11. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
Front Oncol; 2022; 12():978069. PubMed ID: 36330494
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis.
Deng HY; Chen ZJ; Qiu XM; Zhu DX; Tang XJ; Zhou Q
Nutrition; 2021 Oct; 90():111345. PubMed ID: 34166897
[TBL] [Abstract][Full Text] [Related]
13. Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Shen J; Hou H; Liang B; Guo X; Chen L; Yang Y; Wang Y
Front Immunol; 2023; 14():1155104. PubMed ID: 37153578
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
15. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis.
Deng R; Zhang H; Li Y; Shi Y
J Immunother; 2023 Feb-Mar 01; 46(2):43-55. PubMed ID: 36301729
[TBL] [Abstract][Full Text] [Related]
16. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
17. The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Zhang Y; Chen H; Chen S; Li Z; Chen J; Li W
Oncoimmunology; 2021; 10(1):1957605. PubMed ID: 34377596
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis.
Yang T; Hao L; Yang X; Luo C; Wang G; Lin Cai C; Qi S; Li Z
BMJ Open; 2021 Sep; 11(9):e049123. PubMed ID: 34475167
[TBL] [Abstract][Full Text] [Related]
19. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
[TBL] [Abstract][Full Text] [Related]
20. Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis.
Yu S; Zhang S; Xu H; Yang G; Xu F; Yang L; Chen D; An G; Wang Y
BMJ Open; 2023 Mar; 13(3):e059457. PubMed ID: 36931679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
